Advanced secondary lung adenocarcinoma, ALK mutated, from treatment of childhood osteopetrosis.
作者信息
Moffat Gordon Taylor, Davidson Christopher M, Gregg Richard
机构信息
Department of Oncology, Queen's University, Kingston, Ontario, Canada.
Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
出版信息
Pediatr Blood Cancer. 2023 Feb;70(2):e29922. doi: 10.1002/pbc.29922. Epub 2022 Aug 15.
PMID:35969185
Abstract
摘要
相似文献
1
Advanced secondary lung adenocarcinoma, ALK mutated, from treatment of childhood osteopetrosis.
Pediatr Blood Cancer. 2023 Feb;70(2):e29922. doi: 10.1002/pbc.29922. Epub 2022 Aug 15.
2
Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation.
Eur J Cancer. 2022 Apr;165:154-156. doi: 10.1016/j.ejca.2022.02.001. Epub 2022 Feb 27.
3
Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements.
Eur J Cancer. 2022 Jul;169:131-134. doi: 10.1016/j.ejca.2022.04.012. Epub 2022 May 11.
4
A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
J Thorac Oncol. 2021 Apr;16(4):e21-e23. doi: 10.1016/j.jtho.2020.12.016.
5
Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma.
Cancer Commun (Lond). 2023 Aug;43(8):951-955. doi: 10.1002/cac2.12449. Epub 2023 Jun 4.
6
Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors.
Cancer Commun (Lond). 2021 Feb;41(2):183-186. doi: 10.1002/cac2.12128. Epub 2021 Jan 12.
7
ALK-rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib.
Thorac Cancer. 2022 Apr;13(7):1095-1097. doi: 10.1111/1759-7714.14347. Epub 2022 Feb 11.
8
A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
Lung Cancer. 2020 Jul;145:211-212. doi: 10.1016/j.lungcan.2020.04.030. Epub 2020 May 4.
9
Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib.
J Thorac Oncol. 2018 Mar;13(3):e43-e45. doi: 10.1016/j.jtho.2017.10.025.
10
[Clinicopathological analysis of 6 cases of lung adenocarcinoma with concomitant EGFR mutation and ALK fusion].
Zhonghua Bing Li Xue Za Zhi. 2021 Dec 8;50(12):1369-1371. doi: 10.3760/cma.j.cn112151-20210501-00338.
Zotero 插件